GSK2190915 Moderate to Severe Asthma Study

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00850642
First received: February 24, 2009
Last updated: June 14, 2012
Last verified: March 2012
  Purpose

A randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect of treatment with GSK2190915, a FLAP inhibitor, as add-on to current inhaled corticosteroid therapy in patients with moderate to severe asthma with elevated sputum neutrophils.


Condition Intervention Phase
Asthma
Drug: GSK2190195 100mg
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Efficacy of Orally Administered GSK2190915 as an add-on to Current Therapy in Subjects With Moderate to Severe Asthma Who Have Elevated Sputum Neutrophils

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • To evaluate the effect of treatment with repeat oral doses of GSK2190915 on the number of neutrophils in induced sputum in moderate to severe asthmatic subjects compared with placebo. [ Time Frame: The life of the study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the effect of treatment with repeat oral doses of GSK2190915 on lung function as measured by FEV1 in subjects with moderate to severe asthma compared with placebo. [ Time Frame: The life of the study ] [ Designated as safety issue: No ]
  • To assess the safety and tolerability of repeat oral doses of GSK2190915 in moderate to severe asthmatic subjects compared with placebo. [ Time Frame: The life of the study ] [ Designated as safety issue: Yes ]
  • To assess the systemic exposure of GSK2190915 after 12 days repeated doses in moderate to severe asthmatic subjects. [ Time Frame: The life of the study ] [ Designated as safety issue: Yes ]
  • To evaluate the effect of treatment with repeat oral doses of GSK2190915 on LTE4 in urine and LTB4 in blood and sputum supernatant in moderate to severe asthmatic subjects compare to placebo. [ Time Frame: The life of the study ] [ Designated as safety issue: No ]
  • To evaluate the effect of treatment with repeat oral doses of GSK2190915 on IL-17 in blood in moderate to severe asthmatic subjects compare to placebo. [ Time Frame: The life of the study ] [ Designated as safety issue: No ]
  • To evaluate the effect of treatment with repeat oral doses of GSK2190915 in sputum supernatant including changes in neutrophil elastase, myeloperoxidase and IL-8 in moderate to severe asthmatic subjects compare to placebo. [ Time Frame: The life of the study ]
  • To evaluate effect of treatment with repeat oral doses of GSK2190915 on changes in symptoms in moderate to severe asthmatic subjects compare to placebo. [ Time Frame: The life of the study ] [ Designated as safety issue: No ]

Enrollment: 7
Study Start Date: June 2009
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
12 day repeat dosing with placebo
Drug: Placebo

Placebo :

2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)

Experimental: GSK2190915 100mg
12 day repeat dosing treatment phase with 100mg GSK2190915.
Drug: GSK2190195 100mg
GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

A subject will be eligible for inclusion in this study only if all of the following criteria apply:

  • Males and females aged 18 to 65 years inclusive.
  • Body mass index within the range 18.5-37.0 kilograms/metre2 (kg/m2).
  • An established clinical history of Asthma in accordance with the definition by the GINA Guidelines [GINA, 2006]. Subjects should have at screening or within the last year documented reversibility (>12 %) to short acting bronchodilator, or positive methacholine challenge, or positive histamine challenge (PC20 <8mg/ml).
  • A female subject is eligible to participate if she is of: non-childbearing potential defined as pre-menopausal females with documented (medical report verification) hysterectomy or double oophrectomy or postmenopausal defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL and estradiol < 40 pg/ml (<140 pmol/L) or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy; childbearing potential and agrees to use one of the contracception methods listed in Section 8.1 for an appropriate period of time prior to the start of dosing and until 3 months after last dose.
  • Male subjects must agree to use one of the contraception methods listed in Section 8.1. This criterion must be followed from the time of the first dose of study medication until 3 months after the last dose.
  • Subject with moderate to severe asthma with forced expiratory volume in one second (FEV1) ≥ 50% of predicted.
  • Subject who are on regular inhaled corticosteroids without or in combination with a regular long acting Beta 2 Agonist. The dose should be stable for at least 4 weeks before screening.
  • Subjects who are taking a minimum of FP 250mg BID or equivalent.
  • Persistent sputum neutrophilia defined by sputum neutrophils ≥ 65% with TTC < 15 million cells/g with no evidence of eosinophilia (sputum eosinophils < 2%). Persistent is defined as the criteria being met at screening (or within the 6 months preceding screening) and on visit 1.
  • Signed and dated written informed consent is obtained from the subject
  • The subject is able to understand and comply with the protocol requirements, instructions and protocol-stated restrictions.

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  • Past or present disease, which as judged by the investigator or medical monitor, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, gastrointestinal disease, hepatic disease, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease (excluding asthma but including but not confined to chronic bronchitis, emphysema, bronchiectasis, eosinophilic bronchitis or pulmonary fibrosis).
  • Clinically significant abnormalities in safety laboratory analysis at screening.
  • Subject has uncontrolled hypertension or is hypertensive at screening. Hypertension at screening is defined as persistent systolic BP >150 mmHg or diastolic BP > 90mmHg.
  • History of asthma exacerbations or acute intercurrent respiratory illness (viral respiratory syndrome, bronchitis, pneumonia) for a four week period before the screening visit
  • History of life-threatening asthma, defined as an asthma episode that required intubations and/or was associated with hypercapnoea, respiratory arrest and/or hypoxic seizures.
  • Subject is unable to abstain from taking prescription or non-prescription drugs (including vitamins and dietary or herbal supplements) including non-steroidal anti-inflammatory drugs (NSAIDs), anti-depressant drugs, anti-histamines and anti-asthma, anti-rhinitis or hay fever medication, with the exception of ICS, LABA and short action beta agonists, from 14 days before screening until the follow-up visit unless in the opinion of the Investigator and sponsor the medication will not interfere with the study
  • Administration of oral or injectable steroids within 6 weeks of screening.
  • The subject has participated in a study with a new molecular entity during the previous 3 months or has participated in 4 or more clinical studies in the previous 12 months prior to the first dosing day.
  • Administration of anti -leukotrienne therapies for 14 days before screening and during the study.
  • Administration of any vaccinations within 1 month of screening or during the study.
  • Administration of biological therapies within 3 months of the screening visit or during the study
  • Subject is undergoing allergen desensitisation therapy.
  • Administration of OATP1B1 substrates from 2 weeks before dosing, and until all follow-up assessments are completed.
  • There is a risk of non-compliance with study procedures.
  • History of blood donation (500 mL) within 3 months of starting the clinical study.
  • The subject regularly drinks more than 28 units of alcohol in a week if male, or 21 units per week if female. One unit of alcohol is defined as a medium (125 ml) glass of wine, half a pint (250 ml) of beer or one measure (25 ml) of spirits.
  • The subject has a screening QTc value of >450msec, PR interval outside the range 120 to 220msec or an ECG that is not suitable for QT measurements (e.g. poorly defined termination of the T-wave).
  • The subject has tested positive for hepatitis C antibody or hepatitis B surface antigen.
  • The subject has tested positive for HIV antibodies.
  • The subject has a positive pre-study urine drug or urine or breath alcohol screen. A minimum list of drugs that will be screened for include Amphetamines, Barbituates, Cocaine, Opiates, Cannabinoids and Benzodiazepines.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00850642

Locations
Canada, Ontario
GSK Investigational Site
Hamilton, Ontario, Canada, L8N 4A6
GSK Investigational Site
Kingston, Ontario, Canada, K7L 2V6
Canada, Quebec
GSK Investigational Site
Montreal, Quebec, Canada, H4J 1C5
GSK Investigational Site
Sainte-Foy, Quebec, Canada, G1V 4G5
United Kingdom
GSK Investigational Site
Glasgow, Lanarkshire, United Kingdom, G12 0YN
GSK Investigational Site
Leicester, Leicestershire, United Kingdom, LE3 9QP
GSK Investigational Site
Manchester, United Kingdom, M23 9QZ
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00850642     History of Changes
Other Study ID Numbers: 112046
Study First Received: February 24, 2009
Last Updated: June 14, 2012
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
Canada: Health Canada

Keywords provided by GlaxoSmithKline:
Sputum cell counts
Neutrophils
Severe Asthma
ICS
Inhaled corticosteroids

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on September 18, 2014